Second DEP candidate selected by AstraZeneca
Released
Released
Announcement PDF
Second DEP™ candidate selected by AstraZeneca
Melbourne, Australia; 2 December 2015: Starpharma Holdings Ltd (ASX: SPL, OTCQX:
SPHRY) today announced that AstraZeneca has selected a second DEP™ candidate
and Starpharma will now commence a new DEP™ project incorporating the second
proprietary AstraZeneca oncology molecule.
The development of this new DEP™ candidate will be conducted under the recently
signed multi-product license agreement between Starpharma and AstraZeneca. Under
the agreement Starpharma has granted access for the use of its DEP™ drug delivery
platform in the development and commercialisation of AstraZeneca compounds against
a specific drug target. AstraZeneca will fund the joint program.
“Our ongoing collaboration with AstraZeneca is a very positive one and we look forward
to commencing work on the second DEP™ product”, said Dr Jackie Fairley, Chief
Executive Officer of Starpharma.
Starpharma uses its DEP™ technology to improve the performance of pharmaceuticals.
Dendrimer-enhanced versions of selected drugs have been found to be superior to the
unmodified drugs in pre-clinical studies, often having improved efficacy and fewer side
effects or toxicities, such as Starpharma’s drug DEP™ docetaxel which is currently in
Phase 1 clinical studies.
Starpharma Holdings Limited (ASX:SPL, OTCQX:SPHRY), located in Melbourne Australia, is an ASX 300 company and is a
world leader in the development of dendrimer products for pharmaceutical, life science and other applications.
Starpharma’s underlying technology is built around dendrimers – a type of synthetic nanoscale polymer that is highly regular
in size and structure and well suited to pharmaceutical and medical uses. Starpharma has three core development
programs: VivaGel® portfolio, DEP™ drug delivery, and agrochemicals with the Company developing a number of products
internally and others via commercial partnerships.
Starpharma’s lead products are based on VivaGel® (SPL7013, astodrimer sodium), a proprietary dendrimer which has
antimicrobial properties. VivaGel® formulated as a water based gel and delivered vaginally now has EU regulatory approval
for topical treatment and rapid relief of bacterial vaginosis (BV) and is under clinical development for the prevention of
recurrent BV. Starpharma has also signed separate licence agreements with Ansell Limited (ASX:ANN) and Okamoto
Industries. Inc., (TSE: JP3192800005) to market a value-added, VivaGel® condom. The VivaGel® condom is available for
purchase in Australia under Ansell’s Lifestyles® Dual ProtectTM brand. Ansell manufactures and sells leading condom brands
worldwide, including LifeStyles®, ZERO® and SKYN®. Okamoto is the market leader for condoms sold in Japan, which is the
world’s second largest condom market.
In the wider pharmaceutical field, Starpharma has both partnered and internal programs in Drug Delivery. A number of
dendrimer-enhanced, or DEP™ versions of existing drugs are under development. The most advanced of these is DEP™
docetaxel, a dendrimer-enhanced version of docetaxel (Taxotere®), which is in clinical development in patients with solid
tumours. In preclinical studies DEP™ docetaxel has shown significant tumour-targeting and superior anti-cancer effects
across a range of important cancer types including breast, prostate, lung and ovarian tumour, when compared to Taxotere®
(docetaxel). AstraZeneca has signed a licensing agreement with Starpharma for the use of its DEP™ drug delivery platform
in the development and commercialisation of an AstraZeneca oncology compound, with potential for follow on compounds
directed at a defined family of targets.
In agrochemicals Starpharma has a series of partnerships with leading industry players including global leader Adama
(formerly Makhteshim Agan) as well as internal programs including an enhanced version of glyphosate (the active ingredient
in Roundup®). For more information please visit: www.starpharma.com
Media:
Buchan Consulting
Rebecca Wilson
Mob: +61 417 382 391
rwilson@buchanwe.com.au
Gabriella Hold
+61 3 9866 4722
ghold@buchanwe.com.au
Starpharma:
Dr Jackie Fairley, Chief Executive Officer
Nigel Baade, CFO and Company Secretary
+61 3 8532 2704
investor.relations@starpharma.com
www.starpharma.com
Forward Looking Statements
This document contains certain forward-looking statements, relating to Starpharma’s business, which can be identified by the use of
forward-looking terminology such as “promising”, “plans”, “anticipated”, “will”, “project”, “believe”, “forecast”, “expected”, “estimated”,
“targeting”, “aiming”, “set to”, “potential”, “seeking to”, “goal”, “could provide”, “intends”, “is being developed”, “could be”, “on track”, or
similar expressions, or by express or implied discussions regarding potential filings or marketing approvals, or potential future sales of
product candidates. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause
actual results to be materially different from any future results, performance or achievements expressed or implied by such statements.
There can be no assurance that any existing or future regulatory filings will satisfy the FDA’s and other authorities’ requirements regarding
any one or more product candidates nor can there be any assurance that such product candidates will be approved by any authorities for
sale in any market or that they will reach any particular level of sales. In particular, management’s expectations regarding the approval
and commercialization of the product candidates could be affected by, among other things, unexpected trial results, including additional
analysis of existing data, and new data; unexpected regulatory actions or delays, or government regulation generally; our ability to obtain
or maintain patent or other proprietary intellectual property protection; competition in general; government, industry, and general public
pricing pressures; and additional factors that involve significant risks and uncertainties about our products, product candidates, financial
results and business prospects. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove
incorrect, actual results may vary materially from those described herein as anticipated, believed, estimated or expected. Starpharma is
providing this information as of the date of this document and does not assume any obligation to update any forward-looking statements
contained in this document as a result of new information, future events or developments or otherwise.
Page 2 of 2
Share your feedback
Discover